Proteomic and Phosphoproteomic Signatures of Disease Progression in Unmutated IGHV Chronic Lymphocytic Leukemia

ABSTRACT: Chronic lymphocytic leukemia (CLL) patients with an unmutated (UM) immunoglobulin heavy chain variable region gene (IGHV) typically have poorer prognosis and require earlier treatment compared to those with mutated IGHV. Nevertheless, disease progression among UM-CLL patients is heterogeneous, with some experiencing stable disease and prolonged time to first treatment (TTFT). Because the cellular proteome directly reflects cell function, comprehensive proteomic and phosphoproteomic profiling may improve prediction of progression of UM-CLL and uncover novel biomarkers

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Monocyte, Cell Culture

DISEASE(S): Chronic Lymphocytic Leukemia

SUBMITTER: Benjamin Madden  

LAB HEAD: Diane Jelinek Ph.D.

PROVIDER: PXD072006 | Pride | 2026-09-07

REPOSITORIES: Pride